What are Photodynamic therapy agent drugs?

Photodynamic therapy agent drugs are pharmacologic agents that share a common mechanism (typically targeting Vascular endothelial cells (non-receptor mediated phototoxicity)). 3 are currently marketed, with 10 more in clinical development.

What are the marketed Photodynamic therapy agent drugs?

Marketed Photodynamic therapy agent drugs include TOOKAD VTP, Ameluz 10% Topical Gel, BF-200 ALA cream.

Photodynamic therapy agent

3 marketed 6 in Phase 3 4 in Phase 2

This page covers all Photodynamic therapy agent drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Vascular endothelial cells (non-receptor mediated phototoxicity), Protoporphyrin IX (photosensitizer), Protoporphyrin IX (photosensitizer generated from aminolevulinic acid).

Targets

Vascular endothelial cells (non-receptor mediated phototoxicity) · Protoporphyrin IX (photosensitizer) · Protoporphyrin IX (photosensitizer generated from aminolevulinic acid) · Protoporphyrin IX (via aminolevulinic acid metabolism) · Aminolevulinic acid

Marketed (3)

TOOKAD VTP · Steba Biotech S.A. · Oncology
TOOKAD VTP is a vascular-targeting photodynamic therapy agent that generates reactive oxygen species upon light activation to destroy tumor vasculature and induce tumor necrosis.
Ameluz 10% Topical Gel · Psoriasis Treatment Center of Central New Jersey · Dermatology/Oncology
Ameluz is a topical photodynamic therapy agent that generates reactive oxygen species upon light activation to destroy abnormal skin cells.
BF-200 ALA cream · Joint Authority for Päijät-Häme Social and Health Care · Dermatology/Oncology
BF-200 ALA cream is a photodynamic therapy agent that uses aminolevulinic acid to generate reactive oxygen species upon light activation, destroying abnormal skin cells.

Phase 3 pipeline (6)

MAL 16.8% cream · Galderma R&D · Dermatology
MAL 16.8% cream is a topical formulation of methyl aminolevulinate that generates reactive oxygen species upon light activation to destroy abnormal skin cells.
Placebo to BF-200 ALA gel · Biofrontera Bioscience GmbH · Dermatology/Oncology
BF-200 ALA (aminolevulinic acid) gel is a photodynamic therapy agent that generates reactive oxygen species upon light activation to destroy abnormal skin cells.
NDL-PDT · Galderma R&D · Dermatology
NDL-PDT is a photodynamic therapy agent that generates reactive oxygen species upon light activation to destroy targeted tissue.
SUCLEAR® · National Cancer Center, Korea · Oncology
SUCLEAR is a photodynamic therapy agent that generates reactive oxygen species upon light activation to selectively destroy cancer cells.
c-PDT · Galderma R&D · Dermatology
c-PDT is a photodynamic therapy approach that uses a photosensitizing agent activated by light to generate reactive oxygen species and destroy target cells.
TOOKAD® Soluble · Steba Biotech S.A. · Oncology
TOOKAD Soluble is a vascular-targeting photodynamic therapy agent that generates reactive oxygen species upon light activation to destroy tumor vasculature.

Phase 2 pipeline (4)

BF-200 ALA 10% · Biofrontera Bioscience GmbH · Dermatology/Oncology
BF-200 ALA is a topical 5-aminolevulinic acid (ALA) formulation that generates reactive oxygen species upon light activation to destroy abnormal skin cells.
HAL 0.2% with illumination · Photocure · Oncology
Photodynamic therapy with aminolevulinic acid
Broad Area ALA 1-hour incubation · DUSA Pharmaceuticals, Inc. · Dermatology
ALA (5-aminolevulinic acid) is a precursor to porphyrins, which accumulate in abnormal cells and become fluorescent under blue light, allowing for photodynamic therapy.
Broad Area ALA 2 hour incubation · DUSA Pharmaceuticals, Inc. · Dermatology
ALA (5-aminolevulinic acid) is a precursor to porphyrins, which accumulate in abnormal cells and become fluorescent under blue light, allowing for photodynamic therapy.